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CXCR4-SDF-1 interaction potentially
mediates trafficking of circulating tumor
cells in primary breast cancer
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Abstract
Background: Cytokines are involved in cancer invasion and metastasis. Circulating tumor cells (CTCs) play key role
in tumor dissemination and are an independent survival predictor in breast cancer patients. The aim of this study
was to assess correlation between CTCs and plasma cytokines in primary breast cancer (PBC) patients.
Methods: This study included 147 chemotherapy naïve PBC patients. Peripheral blood mononuclear cells (PBMC) were
depleted of hematopoetic cells using RossetteSep™ negative selection kit. RNA extracted from CD45-depleted PBMC
was interrogated for expression of EMT (Twist1, Snail1, Slug, Zeb1) and epithelial (Ck19) gene transcripts by qRT-PCR.
The concentrations of 51 plasma cytokines were measured using multiplex bead arrays.
Results: CTCs were detected in 25.2 % patients. CTCs exhibiting only epithelial markers (CTC_EP) and only EMT markers
(CTC_EMT) were present evenly in 11.6 % patients, while CTCs co-expressing both markers were detected in 2.0 %
patients. Patients with presence of CTC_EP in peripheral blood had significantly elevated levels of plasma IFN-α2, IL-3,
MCP-3, β-NGF, SCF, SCGF-β, TNF-β and SDF-1 compared to patients without CTC_EP. CTC_EP exhibited overexpression
of SDF-1 receptor and CXCR4, but not other corresponding cytokine receptor, and in multivariate analysis SDF-1 was
independently associated with CTC_EP. There was an inverse correlation between CTC_EMT and plasma cytokines
CTACK, β-NGF and TRAIL, while presence of either subtype of CTCs was associated with increased level of TGF-β2.
Conclusion: Using cytokine profiling, we identified cytokines associated with CTCs subpopulations in peripheral blood
of PBC. Our data suggest that CXCR4-SDF-1 axis is involved in mobilization and trafficking of epithelial CTCs.
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Background
Metastatic cascade is a multistep process that enables
the migration of tumor cells from the primary site to a
distant location, where they can potentially establish a
new cancer growth [1]. Circulating tumor cells (CTCs)
are cancer cells that mediate tumor dissemination and
play the key role in the metastatic cascade [1]. Numerous
clinical trials showed the prognostic value of CTCs in
primary as well as in metastatic breast cancer [2–5].
Increasing evidence suggest that CTCs are involved in
tumor growths through the process termed self-seeding,
defined as reinfiltration of the primary tumor or establish-
ment of metastasis by more aggressive CTCs [6]. How-
ever, little is known about exact mechanism of migration
and trafficking of CTCs in peripheral blood circulation.
Metastatic cascade is a highly inefficient process and
only a very limited number of tumor cells that enter the
blood circulation are capable of forming metastases [7–9].
Peripheral blood (PB) constitutes a highly unfavorable
microenvironment for the CTCs owing to physical forces,
the presence of immune cells, and anoikis, all of which
collectively contribute to metastatic insufficiency [10–12].
At the same time, other components of peripheral blood
including platelets, coagulation factors, various signaling
molecules, growth factors and chemokines might protect
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CTCs and affect the selection of target organs for metasta-
ses formation [13].
Chemokines constitute a group of small molecular
weight proteins that play an important role in physio-
logical process like development, cell migration, and
immunity as well as in many pathological conditions
including cancer [14, 15]. The interactions between
chemokines and their respective receptors help to regu-
late the trafficking and organization of cells within vari-
ous tissue compartments [16]. An increasing body of
evidence suggests that chemokines and their receptors
play an important role in cancer progression and metas-
tases formation. They are involved in several processes
significant for cancer pathogenesis including epithelial to
mesenchymal transition, tumor growth, angiogenesis
and/or immunity [16, 17]. The expression of chemokines
and their receptors are aberrant in different types of
hematopoietic and solid tumors including breast cancer,
and it is supposed that interaction between chemokines
and their receptors could be involved in migration of
cancer cells [16].
Composition of peripheral blood could reflect the
activity and burden of the cancer disease. Presence of
CTCs in PB is associated with poor prognosis in breast
cancer, therefore we hypothesized that there are differ-
ences in the composition of peripheral blood based on
the presence and CTCs. Previously we showed differ-
ences in the innate and adaptive immunity in inflamma-
tory breast cancer patients according to presence of
CTCs in PB [18]. We also showed that patients with
CTCs in PB have an increased level of D-dimer, a
marker of coagulation activation [19, 20]. In present
study, we investigated the association between CTCs
and peripheral blood cytokines with the intent of dem-
onstrating which cytokines are involved in CTCs traf-
ficking. To avoid the heterogeneity of metastatic sites
having an effect on analyzed variables, we elected to
study the primary breast cancer model.
Methods
Study patients
As a part of an ongoing translational study (Protocol
TRU-SK 002; Study chair: M. Mego), 147 patients with
stages I–III primary breast cancer (PBC) who were under-
going definitive surgery were included. From each patient
we obtained peripheral blood to assess for the presence of
CTCs as well as for the measuring cytokine/chemokine
levels in plasma. The blood was drawn in the morning on
the day of surgery and prior to surgical procedure. Each
patient was given a complete diagnostic evaluation to
exclude the presence of distant metastasis. Patients with
concurrent malignancy other than non-melanoma skin
cancer in the previous 5 years were excluded as well. In all
patients, data regarding age, tumor stage, histology,
regional lymph node involvement, hormone receptor
status, and HER2 status were also recorded.
The study was approved by the Institutional Review
Board (IRB) and Ethics Committee of the National Cancer
Institute of Slovakia and was conducted between March
2012 and February 2013. Each participant provided written
informed consent before study enrollment. Healthy donors
(N = 60) were age-matched women without breast cancer
who were recruited and consented according to the IRB-
approved protocol.
Detection of CTC in peripheral blood
CTC were detected in 5 mL of peripheral blood depleted
of CD45 positive (CD45+) cells for CTC enrichment
using a quantitative real-time polymerase chain reaction
(qRT-PCR) assay, as described previously [18, 21].
RNA extraction and cell lines
Peripheral blood was subjected to CD45 depletion using
the RossetteSep™ kit (StemCell Technologies, Vancouver,
Canada), according to the manufacturer’s instructions.
CD45-depleted cells were mixed with 300 μl of TRIzol®
LS Reagent (Invitrogen Corporation, Carlsbad, CA) and
stored at − 80 °C. The RNA was extracted from 250 μl of
stored solution according to the manufacturer’s instruc-
tions. The precipitated pellet containing RNA was
dissolved in 25 μl of nuclease-free water. All RNA prep-
aration and handling steps took place in a laminar flow
hood, under RNase-free conditions. RNA concentration
was determined by absorbance readings at 260 nm
(median = 5.95 ng/μl, range: 1.7–38.3 ng/μl). RNA ex-
tracted from HeLa, HCT 116, MCF7 and MDA-MB-
231 cells were used as positive controls.
Identification of gene transcripts in CD45-depleted subsets
Isolated RNA was subjected to quantitative RT-PCR to
detect EMT-inducing transcription factor (TF) gene
transcripts (TWIST1, SNAIL1, SLUG and ZEB1) and
epithelial antigen (KRT19). To detect cytokine recep-
tors on CTCs, we analyzed expression of cytokine re-
ceptor genes in PB enriched for CTCs (CD45-depleted
fraction). For each of tested cytokine receptor gene
expression we analyzed 20 samples (10 CTC_EP posi-
tive and 10 CTCs negative). In brief, 1 μL of RNA were
placed in 20 μL of reaction volume containing 10 μL of
Maxima Probe/ROX qPCR Master Mix (Thermo Scien-
tific), 0.15 μL QuantiFast RT Mix (Qiagen), 7.85 μL water
and 1 μL of primers. The following TaqMan assays were
purchased from LifeTechnologies (USA): TWIST1:
Hs00361186_m1; SNAIL1: Hs00195591_m1; SLUG:
Hs00161904_m1; ZEB1: Hs01566408_m1; GAPDH:
Hs99999905_m1; KRT19 Hs00761767_s1; IFNAR2:
Hs01022060_m1; IL3RA: Hs00608141_m1; CCR1:
Hs00174298_m1; NTRK A: Hs01021011_m1; c-KIT:
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Hs00174029_m1; CXCR4: Hs00607978_s1; LTBR:
Hs00158922_m1. Amplicons or probes spanned intron–
exon boundaries, with the exception of KRT19 and CXCR4.
Amplification was performed on an Roche LightCyler 480
Real-Time PCR system (Roche, Basel, Switzerland) using
the cycling program: 50 °C for 30 min; 95 °C for 10 min;
40 cycles of 95 °C for 15 s and 60 °C for 60 s. All samples
were analyzed in triplicate. Calibrator samples were run
with every plate to ensure consistency of the PCR. For all
fluorescence-based RT-PCR, fluorescence was detected
between 0 and 40 cycles for the control and marker genes
in single-plex reactions, which allowed for the deduction of
the cycles at threshold (Ct) value for each product.
Expression of the genes of interest was calibrated
against expression of the housekeeping gene, GAPDH.
Target cDNA was quantified using the delta-Ct method
with the formula: 1 = 2 Ct(target-GAPDH).
CTC definition
Patient samples with higher KRT19 gene transcripts
than those of healthy donors were scored as epithelial
CTCs positive (CTC_EP), while patient samples with
higher EMT-TF (TWIST1, SNAIL1, SLUG and ZEB1)
gene transcripts than those of healthy donors were
scored as CTC_EMT positive. Expression of at least
one of the markers (either epithelial or mesenchymal)
at levels above the defined cutoff was sufficient to
define a sample as CTC positive.
The highest expression levels of the KRT19 and EMT-
inducing TF gene transcripts relative to that of GAPDH
were 3.4 × 10 −3 (median 2.8 × 10−6, range: 0–3.4 × 10−3)
for KRT19, 7.5 × 10−4 (median 0, range: 0–7.5 × 10−4)
for TWIST1, 3.8 × 10−2 (median 3.1 × 10−3, range: 5.0 ×
10−4–3.8 × 10−2) for SNAIL1 and 1.7 × 10−1 (median
1.4 × 10−2, range: 2.2 × 10−3–1.7 × 10−1) for ZEB1, while
SLUG transcripts were not detected in any of the sam-
ples from healthy donor. These highest expression values
in healthy donors were used as “cutoff” to determine
CTCs positivity.
Plasma isolation
Venous PB samples were collected in EDTA-treated
tubes in the morning on the day of surgery and centri-
fuged at 1000 g for 10 min at room temperature within
2 h of venipuncture and processed, as described previ-
ously [18]. Then, supernatants were collected and centri-
fuged at 1000 g for 10 min at room temperature to
prevent cellular DNA contamination. Plasma samples
were stored at −80 °C until further processing.
Plasma cytokines and angiogenic factors analysis
Plasma samples were analyzed for 51 plasma cytokines and
angiogenic factors: TGF-β1, TGF-β2, TGF-β3, IFN-α2, IL-
1α, IL-2Rα, IL-3, IL-12p40, IL-16, IL-18, CTACK, Gro-α,
HGF, LIF, MCP-3, M-CSF, MIF, MIG, β-NGF, SCF, SCGF-
β, SDF-1α, TNF-β, TRAIL, IL-1β, Il-1RA, IL-2, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17,
Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1,
MIP-1α, MIP-1β, PDGF bb, RANTES, TNF-α, VEGF using
pre-designed panels (Bio-Plex Pro TGF-β assay, Bio-Plex
Pro Human Cytokine 21- and 27-plex immunoassays; Bio-
Rad Laboratories, Hercules, CA, USA). Premixed cytokine
standards and samples were diluted following manufac-
turer’s instructions and incubated with agitation (300 rpm,
RT) with color-coded magnetic beads conjugated with
monoclonal antibodies in the 96-well filter plate for 30 min
(2 h for TGF-β assay). As all three TGF-β isoforms are
secreted as inactive complexes, samples were first activated
with 1 N HCl for 10 min, then neutralized with 1.2 N
NaOH/0.5 M HEPES (Applichem, Darmstadt, Germany)
and assayed immediately after neutralization step. Follow-
ing 3 washes, samples were incubated with biotinylated
detection antibody on a plate shaker (300 rpm agitation,
RT) for 30 min in the dark (1 h for TGF-β). Each captured
analyte was detected by the addition of streptavidin-
phycoerythrin and quantified using a BioPlex suspen-
sion array reader (Bio-Rad Laboratories) equipped with
532 nm reporter laser and 635 nm classification laser
diode. Cytokine concentrations (pg/ml) were calculated
with Bio-Plex Manager 4.0 software using 5-parameter
logistic (5PL) curve fitting.
Statistical analysis
Patient characteristics were tabulated. The patients’ charac-
teristics were summarized using the median (range) for
continuous variables and frequency (percentage) for cat-
egorical variables. Normality of distribution was tested by
the Kolmogorov-Smirnoff test. If normally distributed, sam-
ple means were tested by Student t-test or analysis of vari-
ance (ANOVA) with Bonferroni’s or Tamhane’s corrections,
depending on homogeneity of variance in univariate
analysis. Nonparametric Mann-Whitney U or Kruskal-
Wallis H test were used for non-normally distributed data.
Pearson’s or Spearman’s correlations were used according
to the normality of data. Multivariate logistic regression
analysis included CTC_EP (presence vs. absence), SDF-1
(continuous variable, the base-10 log-transformed due to
significant non-normal distribution), hormone receptor
status (positive for either or negative for both), HER-2
status (overexpressed or negative), tumor grade (1 and 2 vs.
3), tumor stage (T1 vs. ≥ T2) and N stage (N0 vs. N+),
respectively. A backward model selection was conducted,
and the final fitted model is shown in Table 5. All p values
presented are two-sided, and associations were considered
significant if the p value is less or equal to 0.05. Statistical
analyses were performed using NCSS 2007 software
(Hintze J, 2007, Kaysville, Utah, USA).
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Ethical approval
Institutional Review Board, National Cancer Institute,
Bratislava, Slovakia, Protocol TRU-SK 002).
Results
The study population consisted of 147 primary breast
cancer patients with median age of 60 years (range: 35–83
years). Patients’ characteristics are shown in Table 1. There
were 134 (91.2 %) patients with estrogen receptor positive
(ER) and/or progesterone receptor positive (PR) tumors;
21 (14.3 %) patients with HER-2/neu amplified tumors.
Majority of patients had tumor < 2 cm without axillary
lymph nodes involvement, low/intermediate grade.
CTC detection
To determine overexpression of the EMT-inducing TF
gene transcripts and KRT19 in PBC patients, we com-
pared the expression levels in patient samples with those
of HDs. Totally, CTCs were detected in 37 (25.2 %) of
patients. CTCs with only epithelial markers (CTC_EP)
were present in peripheral blood of 17 (11.6 %) patients;
CTC with EMT (CTC_EMT) only phenotype was present
in 17 (11.6 %) of patients; in 3 (2.0 %) of patients, CTCs
exhibited both epithelial and mesenchymal markers
(Table 2). In one patient sample, there was overexpression
of two EMT-inducing TF gene transcripts (SLUG and
TWIST1), e.g. expression of both genes was higher than
the cut-off value in the same sample.
Association between plasma cytokines and CTCs
Patients with presence of CTC_EP in peripheral blood
had significantly elevated levels of plasma IFN-α2, IL-3,
MCP-3, β-NGF, SCF, SCGF-β, SDF-1α, and TNF-β, as
compared to patients without CTC_EP, while there was
inverse correlation between CTC_EP and IL-1α (Table 3).
Moreover there was a trend for positive association
between CTC_EP and IL-2Ra (p = 0.06), MCP-1 (p =
0.08), IL-16 (p = 0.08) and TGF-β2 (p = 0.09).
There were no positive association between CTC_EMT
and plasma cytokines; however, patients with CTC_EMT
had significantly decreased plasma levels of CTACK,
β −NGF and TRAIL, as compared to patients without
CTC_EMT as well as a trend for inverse association
between CTC_EMT and SDF-1 (p = 0.06), IFN-α2 (p =
0.06) and IL-3 (p = 0.08) (Table 3). Moreover, patients
with any CTCs (epithelial or mesenchymal) in periph-
eral blood had significantly elevated level of TGF-β2
and decreased level of IL-1α (Table 3).
Expression of cytokine receptors in peripheral blood
enriched for CTCs
Based on an observed association between CTC_EP and
cytokines, the following corresponding cytokine receptors
were detected in PB enriched for CTC_EP (CD45 depleted
PB with KRT19 overexpression); IFNAR2 (interferon-
alpha/beta receptor beta chain) for IFN-α2, IL3RA (inter-
leukin 3 receptor alpha) for IL-3, CCR1 (chemokine (C-C
motif) receptor 1) for MCP-3, NTRK A (tropomyosin
receptor kinase A) for β-NGF, c-KIT (mast/stem cell
growth factor receptor) for SCF and SCGF-β, CXCR4 for
SDF-1α and LTBR (lymphotoxin beta receptor) for TNF-
β. CTC_EP samples had a significantly higher expression
of CXCR4 compared with those of CTC negative samples
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0 93 63.3
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Invasive ductal carcinoma 127 86.4
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Hormone receptor status
Negative for both 13 8.8
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(Table 4, Fig. 1), while there was no statistically significant
difference in any of the remaining corresponding cyto-
kines receptors (Table 4).
Multivariate analysis of association between SDF-1 and
Epithelial CTCs
In univariate analysis, we found association of several
plasma cytokines and CTC_EP; however, only chemo-
kine receptor for SDF-1 cytokine (CXCR4) was detected
in PB enriched for CTC_EP. Therefore, we build multi-
variate regression model to analyze if SDF-1 is associated
with CTC_EP independently of known prognostic factors
including T and N stage, hormone and HER-2/neu recep-
tor status and tumor grade, respectively (Table 5). This
analysis confirmed that plasma SDF-1 level is independ-
ently correlated with CTC_EP in peripheral blood.
Discussion
In this prospective translational study, we showed for
the first time an association between different subsets of
CTCs and plasma cytokines in primary breast cancer
patients. Several plasma cytokines positively correlated
with presence of epithelial CTCs in the peripheral blood,
while CTC_EMT phenotype inversely correlated with
CTACK, β-NGF and TRAIL. Interestingly, an increased
plasma level of TGF-β2 positively correlated with pres-
ence of any subset of CTCs. To determine which cyto-
kines are involved in CTCs trafficking, we evaluated
expression of cytokine receptors in PB enriched for
CTC_EP, corresponding to cytokines that are positively
associated with CTC_EP. Among seven evaluated recep-
tors, only CXCR4, receptor for SDF-1, was overexpressed
in this PB fraction implicating that the CXCR4-SDF-1 axis
is mainly involved in trafficking and homing of epithelial
CTCs. Multivariate analysis showed that SDF-1 is
independently associated with CTC_EP, as previously re-
ported [22], stressing the significance of CXCR4-SDF-1 axis
for epithelial CTCs [23]. Numerically, other chemokine
receptors seemed to be overexpressed on CTC_EP; there-
fore, we can’t exclude the involvement of these receptors in
the trafficking and homing of CTCs, as well. Due to
Table 2 CTC detection and expression of the genes in CD45-
depleted peripheral blood at levels higher than those of
healthy donors






CTC_EP only 17 11.6




Any CTC 37 25.2
aIn one patient sample, there was overexpression of two EMT-inducing TF
gene transcripts (SLUG and TWIST1)
bIn one sample there was co-overexpression of KRT19 and SLUG, while in other
two samples there was co-overexpression of KRT19 and TWIST1
Table 3 Association between CTCs and plasma cytokines
Cytokine Mean SEM Median P-value
IFN-α2 (ng/mL)
CTC_EP - 100.52 2.01 98.45 0.002
CTC_EP+ 116.29 4.84 112.74
IL-3 (ng/mL)
CTC_EP - 40.76 2.90 33.21 0.029
CTC_EP+ 52.48 6.77 52.83
MCP-3 (ng/mL)
CTC_EP - 53.82 3.53 44.01 0.013
CTC_EP+ 73.17 8.29 79.21
β-NGF (ng/mL)
CTC_EP - 1.25 0.18 0.86 0.002
CTC_EP+ 1.52 0.44 1.31
SCF (ng/mL)
CTC_EP - 51.52 2.61 44.74 0.004
CTC_EP+ 68.62 6.48 69.91
SCGF-β (ng/mL)
CTC_EP - 17377.49 820.65 15565.08 0.008
CTC_EP+ 22633.38 2029.19 20271.15
SDF-1α (ng/mL)
CTC_EP - 223.75 9.35 219.53 0.036
CTC_EP+ 265.86 22.85 262.79
TNF-β (ng/mL)
CTC_EP - 0.47 0.04 0.37 0.008
CTC_EP+ 0.67 0.11 0.71
CTACK (ng/mL)
CTC_EMT - 1394.47 43.93 1343.50 0.046
CTC_EMT+ 1185.51 110.71 1055.12
β − NGF (ng/mL)
CTC_EMT - 1.38 0.17 0.95 0.046
CTC_EMT+ 0.77 0.43 0.77
TRAIL (ng/mL)
CTC_EMT - 50.57 2.83 44.37 0.044
CTC_EMT+ 37.91 7.21 29.28
TGF-β2 (ng/mL)
Any CTC - 2099.93 61.43 2052.98 0.016
Any CTC+ 2395.52 102.38 2227.53
Abbreviations: SEM standard error of the mean, CTC_EP – epithelial circulating
tumor cells absent, CTC_EP+ epithelial circulating tumor cells absent, CTC_EMT
mesenchymal circulating tumor cells absent, CTC_EMT+,– mesenchymal
circulating tumor cells present
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chemokine promiscuity other chemokine receptors might
also elaborate in these processes [24].
Previously, numerous studies suggest importance of
CXCR4-SDF-1 axis in tumor dissemination and cancer
progression [25–27]. CXCR4 overexpression in tumor
tissue was associated with inferior outcome in several
cancers including breast cancer [28]. Moreover, expres-
sion of CXCR4 on cancer cells was associated with
cancer stem cell phenotype and treatment resistance
[29]. Previously, it was showed that CXCR4 is involved
in homing of breast cancer cells predominantly to bone
and liver [30, 31], however, this is a first study that
revealed CXCR4 overexpression in the PB enriched for
epithelial CTCs, and first study that showed clear associ-
ation between plasma level of CXCR4 ligand SDF-1 and
subset of CTCs with epithelial phenotype. In previous
study, we correlated SDF-1 expression in tumor tissue
with presence of CTCs (manuscript submitted), and
there was no correlation between epithelial CTCs and
expression of SDF-1 in primary tumor tissue, nor correl-
ation between plasma and tissue SDF-1 level (data not
shown), suggesting, that source of plasma SDF-1, that
attracts CTCs into circulation, is outside the primary
breast tumor. CXCR4 antagonists, were first evaluated in
the treatment of HIV, later was discovered their poten-
tial for mobilizing CD34+ hematopoietic peripheral stem
cells, but these classes of drugs are promising anticancer
drugs and several clinical trials are ongoing including
breast cancer [23, 32–34]. Recently it was shown, that
CXCR4 signaling regulates breast cancer stem cell activ-
ities and thus could be important in tumour formation
at the sites of metastases. In vitro, it was observed a
greater reduction in self-renewal following CXCR4 in-
hibition in the CXCR4 over-expressing cells compared
to cells without CXCR4 overexpression [35]. Based on
observed data, we suggest, that CXCR4 antagonist could
affect mobilization and trafficking of CTCs as well as
self-renewal capacity of cancer cells and thus could
represent promising drugs in breast cancer. At the same
time, we suppose that expression of CXCR4 on CTCs
could represent a novel marker for selection of anti-
CXCR4 therapy [22].
Beyond the role in CTCs trafficking, elevated plasma
levels of IFN-α2, IL-3, MCP-3, β-NGF, SCF, SCGF-β,
TNF-β and SDF-1α in patients with CTC_EP could reflect
more aggressive disease and/or activation of immune
system as a host reaction to CTCs in peripheral blood. In
particular, IFN-α2, IL-3, and TNF-β are cytokines involved
in inflammation and anticancer immunity, and their posi-
tive association with CTC_EP might be due to activation
of anticancer immunity. However, many tumors including
breast cancer may endorse immune tolerance to facilitate
tumor growth utilizing different cytokines including SCF
and SCGF-β that are responsible for recruiting and/or ac-
tivating immune suppressor cells, such as myeloid-derived
suppressor cells [36]. Other cytokines including β-NGF
might promote tumor growth through regulating breast
cancer stem cell self-renewal and plasticity [37].
We observed inverse correlation between CTC_EMT
and plasma cytokines CTACK, β-NGF and TRAIL. EMT
is a transdifferentiation process that plays an important
role in tumor invasion and release of CTCs into the per-
ipheral circulation. Beside its role in CTCs generation,
EMT is closely related to immunity and induces im-
paired dendritic cells and T-regulatory cells, suggesting
an immunosuppressive effect of EMT, as showed previ-
ously [17, 38]. Therefore, an inverse association between
observed cytokines and CTC_EMT phenotype might re-
flect EMT induced immunosuppression. Tumor growth
factor β2 (TGF-β2) correlated with presence of any
Table 4 Expression of chemokine receptors on CTC_EP
Chemokine receptor CTC_EP – CTC_EP+ p-value
CCR1
























Mean 0.0530 0.0735 0.60
SEM 0.0162 0.0162
Median 0.0511 0.0559
Abbreviations: SEM standard error of the mean, CTC_EP – epithelial circulating
tumor cells absent, CTC_EP+ epithelial circulating tumor cells absent
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subset of CTCs (CTC_EP and/or CTC_EMT) in periph-
eral blood. Although TGF-β2 works as a tumor suppres-
sor during cancer initiation, it may act as a tumor
promoter during tumor progression and is involved in
multiple processes in tumor progression such as in indu-
cing of EMT [39]. Previously, we showed abnormalities
in the innate and adaptive immunity of IBC patients
with ≥1 CTCs and ≥5 CTCs per 7.5 mL of peripheral
blood and observed that an association between cyto-
kines and CTCs might suggest impaired activity of the
immune system in patients with CTCs in peripheral
blood [12].
Numerous methods are currently utilized for CTCs
detection and characterization capable to determine
different subpopulations of CTCs with different clinical
and biological value [11]. Therefore, all data regarding
CTCs should be interpreted within the context of the
detection method used. In this study, we detected CTCs
indirectly, by qRT-PCR method, based on expression of
KRT19 and EMT-TFs respectively. We defined CTC_EP
based on expression of KRT19, an epithelial marker,
commonly utilized for CTCs detection with established
prognostic value in breast cancer [5]. However, due to
p = 0.03
p = 0.04
Fig. 1 a SDF-1 in plasma of patients with none CTCs vs. CTC_EP (mean ± SEM = 223.75 ± 9.35 vs. 265.86 ± 22.85, p = 0.04). b Expression of CXCR4
(SDF-1 receptor) in peripheral blood enriched for CTCs (CD45 depleted) in patients with none CTCs vs. CTC_EP (relative expression ± SEM= 0.0433 ±
0.0275 vs. 0.1191 ± 0.0814, p = 0.03)









SDF-1 16.90 0.91 314.67 0.03
(continous variable, log)
T-stage 1.03 0.32 3.38 0.97
T1 vs. ≥ T2
N-stage 0.88 0.30 2.60 0.81
N0 vs. N+
Grade 0.62 0.21 1.82 0.38
1 and 2 vs. 3
ER/PR status 3.13 0.76 12.96 0.13
Negative for both
vs. positive for either
HER2/neu status 1.64 0.33 8.20 0.52
Negative vs. overexpressed
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CTCs heterogeneity, it remains to determine the associa-
tions between SDF-1 cytokine and other subsets of epithe-
lial CTCs that lack KRT19 overexpression. In our study, we
used four EMT-TFs for detection of CTC_EMT, known to
play a role in breast cancer pathogenesis [17, 20, 40–43].
We observed overexpression of two of them (SLUG
and TWIST1) in some patients, while detection of
SNAIL1 and ZEB1 doesn’t contributed to CTCs detec-
tion. We hypothesize, that this could be due to background
expression of SNAIL1 and ZEB1 in CD45 depleted periph-
eral blood, that mask possible signal from CTCs overex-
pressing these two EMT related genes.
Conclusion
In conclusion, the results of this prospective translational
study suggest that specific cytokines, particularly the
CXCR4-SDF-1 axis might be involved in the trafficking
and homing of CTCs or alternatively, increased levels of
these cytokines could be a marker of more aggressive
disease. Thus, therapeutic inhibition of this signaling path-
way could represent a novel therapeutic target interfering
with tumor dissemination and metastatic cascade in
primary breast cancer patients.
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